Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Diazepam treatment of early signs of exacerbation in schizophrenia.

Carpenter WT Jr, Buchanan RW, Kirkpatrick B, Breier AF.

Am J Psychiatry. 1999 Feb;156(2):299-303.

PMID:
9989567
2.

Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia.

Marder SR, Wirshing WC, Van Putten T, Mintz J, McKenzie J, Johnston-Cronk K, Lebell M, Liberman RP.

Arch Gen Psychiatry. 1994 Apr;51(4):280-7.

PMID:
8161288
3.

Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia.

Wolkowitz OM, Pickar D, Doran AR, Breier A, Tarell J, Paul SM.

Am J Psychiatry. 1986 Jan;143(1):85-7.

PMID:
2867690
4.

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.

Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG.

Arch Gen Psychiatry. 1997 Jun;54(6):549-57.

PMID:
9193196
5.

Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.

Dellva MA, Tran P, Tollefson GD, Wentley AL, Beasley CM Jr.

Psychiatr Serv. 1997 Dec;48(12):1571-7.

PMID:
9406266
6.

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.

Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE.

Arch Gen Psychiatry. 2005 Nov;62(11):1196-204.

PMID:
16275807
7.

Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.

Woods SW, Gueorguieva RV, Baker CB, Makuch RW.

Arch Gen Psychiatry. 2005 Sep;62(9):961-70. Review.

PMID:
16143728
8.

Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms.

Arango C, Kirkpatrick B, Buchanan RW.

J Nerv Ment Dis. 2000 Jan;188(1):50-3. No abstract available.

PMID:
10665462
9.

A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.

Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, Taylor CC, Palmer R, Dossenbach M, Kiesler G, Brook S, Wright P.

Arch Gen Psychiatry. 2002 May;59(5):441-8.

PMID:
11982448
10.

A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia.

Chengappa KN, Goldstein JM, Greenwood M, John V, Levine J.

Clin Ther. 2003 Feb;25(2):530-41.

PMID:
12749512
11.

The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group.

Kramer MS, Last B, Getson A, Reines SA.

Arch Gen Psychiatry. 1997 Jun;54(6):567-72. Erratum in: Arch Gen Psychiatry 1997 Dec;54(12):1080.

PMID:
9193198
12.

The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials.

Kane JM, Assunção-Talbott S, Eudicone JM, Pikalov A, Whitehead R, Crandall DT.

Schizophr Res. 2008 Oct;105(1-3):208-15. doi: 10.1016/j.schres.2008.06.018. Epub 2008 Sep 14. Erratum in: Schizophr Res. 2009 Feb;107(2-3):334-5.

PMID:
18790605
13.

A placebo-controlled, double-blind comparison of clobazam and diazepam in the treatment of anxiety.

Jacobson AF, Goldstein BJ, Dominguez RA, Steinbook RM.

J Clin Psychiatry. 1983 Aug;44(8):296-300.

PMID:
6135690
14.

Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.

Breier AF, Malhotra AK, Su TP, Pinals DA, Elman I, Adler CM, Lafargue RT, Clifton A, Pickar D.

Am J Psychiatry. 1999 Feb;156(2):294-8.

PMID:
9989566
15.

Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia.

Dossenbach MR, Folnegovic-Smalc V, Hotujac L, Uglesic B, Tollefson GD, Grundy SL, Friedel P, Jakovljevic MM; Olanzapine HGCH Study Group.

Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):311-8.

PMID:
14751428
16.

Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia.

Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, Weizman A.

Arch Gen Psychiatry. 2003 Feb;60(2):133-41.

PMID:
12578430
17.

Pharmacotherapy of impaired affect in recovering schizophrenic patients.

Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL, Bartone P, Cooley S, Hammill K, Carter M, Munetz MR, Perel J.

Arch Gen Psychiatry. 1995 Jan;52(1):29.

PMID:
7811160
19.

Placebo-controlled trial of glycine added to clozapine in schizophrenia.

Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC.

Am J Psychiatry. 2000 May;157(5):826-8.

PMID:
10784481
20.

A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.

Anil Yağcioğlu AE, Kivircik Akdede BB, Turgut TI, Tümüklü M, Yazici MK, Alptekin K, Ertuğrul A, Jayathilake K, Göğüş A, Tunca Z, Meltzer HY.

J Clin Psychiatry. 2005 Jan;66(1):63-72.

PMID:
15669890
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk